Personalized inherent randomness of the immune system is manifested by an individualized response to immune triggers and immunomodulatory therapies: a novel platform for designing personalized immunotherapies
- 22 Downloads
The considerable variability of responses amongst subjects to disease triggers and immunotherapies is a major obstacle to designing better immune-based therapies. Therefore, development of patient-tailored precision medicine that improves the efficacy of immunomodulatory drugs is necessary. The individualized response to disease triggers and immunomodulatory therapies was studied using the concanavalin A (ConA) immune-mediated hepatitis model and the oral administration of anti CD3 or β-glucosylceramide (GC). Mice were treated with anti-CD3 antibodies or GC followed by an injection of ConA. The effects of these treatments on liver damage and the immune profile were then analyzed. An individualized response to ConA and orally administered immunomodulatory agents was observed in eight consecutive experiments. While alleviation of the immune-mediated liver injury, as measured by serum levels of liver enzymes, was seen, and high intra-group and inter-experimental variabilities were detected. A similar individualized response was observed for the effect on serum levels of IFN-γ, TNF-α, and IL-10 and on CD4+CD25+, CD8+CD25+, and CD3+NK1.1+ lymphocytes. A personalized form of inherent randomness in an isolated system was documented, which may underlie the variability in responses to immune triggers and immunomodulatory therapies. The data support the use of personalized randomness-based platforms for improving the response to chronic therapies.
KeywordsPrecision medicine Patient-tailored therapy Autoimmune disease Immunomodulation NKT cells
Natural killer T
Tumor necrosis factor alpha
Programmed death-ligand 1
Compliance with ethical standards
Animal experiments were carried out according to the guidelines of the Hebrew University-Hadassah Institutional Committee for the Care and Use of Laboratory Animals and with the committee’s approval.
Conflict of interest
YI is a founder of Oberon Sciences and consultant for Teva, ENZO, Protalix, Betalin Therapeutics, Immuron, SciM, Natural Shield, Tiziana Pharma, Plantylight, and Exalenz Bioscience.
- 8.Wardill HR, Tissing WJE. Determining risk of severe gastrointestinal toxicity based on pretreatment gut microbial community in patients receiving cancer treatment: a new predictive strategy in the quest for personalized cancer medicine. Curr Opin Support Palliat Care. 2017;11(2):125–32. https://doi.org/10.1097/SPC.0000000000000265.CrossRefPubMedGoogle Scholar
- 12.Ogura M, Deng S, Preston-Hurlburt P, Ogura H, Shailubhai K, Kuhn C, et al. Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in humanized mice. Clin Immunol. 2017;183:240–6. https://doi.org/10.1016/j.clim.2017.07.005.CrossRefPubMedGoogle Scholar
- 15.Wu HY, Maron R, Tukpah AM, Weiner HL. Mucosal anti-CD3 monoclonal antibody attenuates collagen-induced arthritis that is associated with induction of LAP+ regulatory T cells and is enhanced by administration of an emulsome-based Th2-skewing adjuvant. J Immunol. 2010;185(6):3401–7. https://doi.org/10.4049/jimmunol.1000836.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Ilan Y, Maron R, Tukpah AM, Maioli TU, Murugaiyan G, Yang K, et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci U S A. 2010;107(21):9765–70. https://doi.org/10.1073/pnas.0908771107.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Ilan Y. Review article: novel methods for the treatment of non-alcoholic steatohepatitis - targeting the gut immune system to decrease the systemic inflammatory response without immune suppression. Aliment Pharmacol Ther. 2016;44(11-12):1168–82. https://doi.org/10.1111/apt.13833.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Ilan Y, Zigmond E, Lalazar G, Dembinsky A, Ben Ya'acov A, Hemed N, et al. Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells. J Clin Immunol. 2010;30(1):167–77. https://doi.org/10.1007/s10875-009-9323-7.CrossRefPubMedGoogle Scholar
- 21.Lalazar G, Mizrahi M, Turgeman I, Adar T, Ben Ya'acov A, Shabat Y, et al. Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial. J Clin Immunol. 2015;35(4):399–407. https://doi.org/10.1007/s10875-015-0160-6.CrossRefPubMedGoogle Scholar
- 22.Halota W, Ferenci P, Kozielewicz D, Dybowska D, Lisovoder N, Samira S, et al. Oral anti-CD3 immunotherapy for HCV-nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase-2a placebo-controlled trial. J Viral Hepat. 2015;22(8):651–7. https://doi.org/10.1111/jvh.12369.CrossRefPubMedGoogle Scholar
- 23.Ilan Y. Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol. 2016;310(11):G1102–17. https://doi.org/10.1152/ajpgi.00095.2016.CrossRefPubMedGoogle Scholar
- 27.Shuvy M, Ben Ya'acov A, Zolotarov L, Lotan C, Ilan Y. Beta glycosphingolipids suppress rank expression and inhibit natural killer T cell and CD8+ accumulation in alleviating aortic valve calcification. Int J Immunopathol Pharmacol. 2009;22(4):911–8. https://doi.org/10.1177/039463200902200406.CrossRefPubMedGoogle Scholar
- 28.Lalazar G, Ben Ya'acov A, Livovsky DM, El Haj M, Pappo O, Preston S, et al. Beta-glycoglycosphingolipid-induced alterations of the STAT signaling pathways are dependent on CD1d and the lipid raft protein flotillin-2. Am J Pathol. 2009;174(4):1390–9. https://doi.org/10.2353/ajpath.2009.080841.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Ben Ya'acov A, Lalazar G, Livovsky DM, Kanovich D, Axelrod E, Preston S, et al. Decreased STAT-1 phosphorylation by a thio analogue of beta-D-glucosylceramide is associated with altered NKT lymphocyte polarization. Mol Immunol. 2009;47(2-3):526–33. https://doi.org/10.1016/j.molimm.2009.07.030.CrossRefPubMedGoogle Scholar
- 31.Livovsky DM, Lalazar G, Ben Ya'acov A, Pappo O, Preston S, Zolotaryova L, et al. Administration of beta-glycolipids overcomes an unfavorable nutritional dependent host milieu: a role for a soy-free diet and natural ligands in intrahepatic CD8+ lymphocyte trapping and NKT cell redistribution. Int Immunopharmacol. 2008;8(9):1298–305. https://doi.org/10.1016/j.intimp.2008.05.005.CrossRefPubMedGoogle Scholar
- 32.Lalazar G, Ben Ya'acov A, Eliakim-Raz N, Livovsky DM, Pappo O, Preston S, et al. Beta-glycosphingolipids-mediated lipid raft alteration is associated with redistribution of NKT cells and increased intrahepatic CD8+ T lymphocyte trapping. J Lipid Res. 2008;49(9):1884–93. https://doi.org/10.1194/jlr.M800113-JLR200.CrossRefPubMedGoogle Scholar
- 34.Lalazar G, Zigmond E, Weksler-Zangen S, Ya'acov AB, Levy MS, Hemed N, et al. Oral Administration of beta-Glucosylceramide for the Treatment of Insulin Resistance and Nonalcoholic Steatohepatitis: Results of a Double-Blind. Placebo-Controlled Trial J Med Food. 2017;20(5):458–64. https://doi.org/10.1089/jmf.2016.3753.CrossRefPubMedGoogle Scholar
- 38.Lalazar G, Ben Ya'acov A, Lador A, Livovsky DM, Pappo O, Preston S, et al. Modulation of intracellular machinery by beta-glycolipids is associated with alteration of NKT lipid rafts and amelioration of concanavalin-induced hepatitis. Mol Immunol. 2008;45(13):3517–25. https://doi.org/10.1016/j.molimm.2008.05.009.CrossRefPubMedGoogle Scholar
- 39.Mizrahi M, Lalazar G, Ben Ya'acov A, Livovsky DM, Horowitz Y, Zolotarov L, et al. Beta-glycoglycosphingolipid-induced augmentation of the anti-HBV immune response is associated with altered CD8 and NKT lymphocyte distribution: a novel adjuvant for HBV vaccination. Vaccine. 2008;26(21):2589–95. https://doi.org/10.1016/j.vaccine.2008.03.026.CrossRefPubMedGoogle Scholar
- 40.Elinav E, Pappo O, Sklair-Levy M, Margalit M, Shibolet O, Gomori M, et al. Amelioration of non-alcoholic steatohepatitis and glucose intolerance in ob/ob mice by oral immune regulation towards liver-extracted proteins is associated with elevated intrahepatic NKT lymphocytes and serum IL-10 levels. J Pathol. 2006;208(1):74–81. https://doi.org/10.1002/path.1869.CrossRefPubMedGoogle Scholar
- 46.Aabakken L, Karlsen TH, Albert J, Arvanitakis M, Chazouilleres O, Dumonceau JM, et al. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Endoscopy. 2017;49(6):588–608. https://doi.org/10.1055/s-0043-107029.CrossRefPubMedGoogle Scholar
- 50.Brzustewicz E, Bzoma I, Daca A, Szarecka M, Bykowska MS, Witkowski JM, et al. Heterogeneity of the cytokinome in undifferentiated arthritis progressing to rheumatoid arthritis and its change in the course of therapy. Move toward personalized medicine. Cytokine. 2017;97:1–13. https://doi.org/10.1016/j.cyto.2017.05.012.CrossRefPubMedGoogle Scholar
- 53.Ilan Y. Advanced Tailored Randomness: A Novel Approach for Improving the Efficacy of Biological Systems. J Comput Biol. 2019. https://doi.org/10.1089/cmb.2019.0231.
- 66.Sima CA, Inskip JA, Sheel AW, van Eeden SF, Reid WD, Camp PG. The reliability of short-term measurement of heart rate variability during spontaneous breathing in people with chronic obstructive pulmonary disease. Rev Port Pneumol (2006). 2017;23(6):338–42. https://doi.org/10.1016/j.rppnen.2017.06.001.CrossRefGoogle Scholar